Trajectories of cognitive decline following dementia onset: What accounts for variation in progression?

Dementia and Geriatric Cognitive Disorders

Volumn 31, Issue 3, 2011, Pages 202-209

  MacDonald, Stuart W S ^a,b   Karlsson, Sari ^a   Fratiglioni, Laura ^a   Bäckman, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Alzheimer's disease; Cognition; Dementia; Disease progression; Postdementia cognitive change, predictors of

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEMENTIA; EDUCATIONAL STATUS; FEMALE; HUMAN; ILLNESS TRAJECTORY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NORMAL HUMAN; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; AGING; CASE-CONTROL STUDIES; COGNITION; COGNITION DISORDERS; COHORT STUDIES; DEMENTIA; DISEASE PROGRESSION; GERIATRIC ASSESSMENT; HUMANS; LONGITUDINAL STUDIES; MODELS, PSYCHOLOGICAL; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX;

EID: 79952826821     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000325666     Document Type: Article

References (41)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M: Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117. (Pubitemid 41797645)
2. Bäckman L, Wahlin A, Small BJ, Herlitz A, Winblad B, Fratiglioni L: Cognitive functioning in aging and dementia: the Kungsholmen Project. Aging Neuropsychol Cogn 2004; 11: 212-244. (Pubitemid 39387203)
3. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
4. Feldman HH, Woodward MM: The staging and assessment of moderate to severe Alzheimer disease. Neurology 2005; 65(suppl 3):S10-S17. (Pubitemid 41362109)
5. Doody RS, Massman P, Dunn JK: A method for estimating progression rates in Alzheimer disease. Arch Neurol 2001; 58: 449-454. (Pubitemid 32217462)
6. Atchison TB, Bradshaw M, Massman PJ: Investigation of profile difference between Alzheimers disease patients declining at different rates: examination of baseline neuropsychological data. Arch Clin Neuropsychol 2004; 19: 1007-1015. (Pubitemid 39472666)
7. Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, van Belle G, Fillenbaum G, Heyman A: The Consortium to Establish a Registry for Alzheimers Disease (CERAD). Part 4. Rates of cognitive change in the longitudinal assessment of probable Alzhei mers disease. Neurology 1993; 43: 2457-2465.
8. Growdon JH, Locascio JJ, Corkin S, Gomez- Isla T, Hyman BT: Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimers disease. Neurology 1996; 47: 444-448. (Pubitemid 26324041)
9. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS: Individual growth curve analysis of APOE ε4 -associated cognitive decline in Alzheimer disease. Arch Neurol 2005; 62: 454-459. (Pubitemid 40349483)
10. Storandt M, Grant EA, Miller JP, Morris JC: Rates of progression in mild cognitive impairment and early Alzheimers disease. Neurology 2002; 59: 1034-1041.
11. Morris JC: Dementia update 2005. Alzheimer Dis Assoc Disord 2005; 19: 100-117. (Pubitemid 41073088)
12. Andel R, Vigen C, Mack W, Gatz M: The effect of education and occupational complexity on rate of cognitive decline in Alzheimers patients. J Int Neuropsychol Soc 2006; 12: 147-152. (Pubitemid 43379961)
13. Martins CAR, Oulhaj A, de Jager CA, Williams JH: APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology 2005; 65: 1888-1893. (Pubitemid 43970105)
14. Scarmeas N, Albert SM, Manly JJ, Stern Y: Education and rates of cognitive decline in incident Alzheimers disease. J Neurol Neurosurg Psychiatry 2006; 77: 308-316.
15. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, Blacker D, Stern Y: APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 2008; 70: 1842-1849. (Pubitemid 351653957)
16. Farlow MR, Small GW, Quarg P, Krause A: Efficacy of rivastigmine in Alzheimers disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord 2005; 20: 192-197. (Pubitemid 41191637)
17. Wild KV, Kaye JA: The rate of progression of Alzheimers disease in the later stages: evidence from the Severe Impairment Battery. J Int Neuropsychol Soc 1998; 4: 512-516. (Pubitemid 28461622)
18. Winblad B, Kilander L, Eriksson S, Minthon L, Batsman S, Wetterholm AL, Jansson-Blixt C, Haglund A: Donepezil in patients with severe Alzheimers disease: double-blind, parallel- group, placebo-controlled study. Lancet 2006; 367: 1057-1065.
19. Fratiglioni L, Viitanen M, von Strauss E, Tontodonati V, Herlitz A, Winblad B: Very old women at highest risk of dementia and Alzheimers disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997; 48: 132-138. (Pubitemid 27039531)
20. Fratiglioni L, Grut M, Forsell Y, Viitanen M, Grafström M, Holmén K, Ericsson K, Äckman L, Ahlbom A, Winblad B: Prevalence of Alzheimers disease and other dementias in an elderly urban population: relationship with age, sex and education. Neurology 1991; 41: 1886-1892.
21. Laukka EJ, MacDonald SWS, Bäckman L: Contrasting cognitive trajectories of impending death and preclinical dementia in the very old. Neurology 2006; 66: 833-838. (Pubitemid 43739756)
22. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3, rev. Washington, American Psychiatric Association, 1987.
23. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
24. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S: Apolipoprotein E polymorphism and Alzheimers disease. Lancet 1993; 342: 697-699.
25. Huang W, Qiu C, von Strauss E, Winblad B, Fratiglioni L: APOE genotype, family history of dementia and Alzheimer disease risk: a 6-year follow-up study. Arch Neurol 2004; 61: 1930-1934. (Pubitemid 39612954)
26. Qiu C, Winblad B, Fastbom J, Fratiglioni L: Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology 2003; 61: 655-660. (Pubitemid 37082603)
27. Bäckman L, Jones S, Small BJ, Agüero-Torres H, Fratiglioni L: Rate of cognitive decline in preclinical Alzheimers disease: the role of comorbidity. J Gerontol B Psychol Sci Soc Sci 2003; 58:P228-P236. (Pubitemid 36903986)
28. Forsell Y, Jorm AF, Fratiglioni L, Grut M, Winblad B: Application of DSM-III-R criteria for major depressive episode to elderly subjects with and without dementia. Am J Psychiatry 1993; 150: 1199-1202. (Pubitemid 23218901)
29. Fratiglioni L, Wang HX, Ericsson K, Maytan M, Winblad B: Influence of social network on occurrence of dementia: a communitybased longitudinal study. Lancet 2000; 355: 1315-1319. (Pubitemid 30199003)
30. 12 and folate in relation to the development of Alzheimers disease. Neurology 2001; 56: 1188-1194. (Pubitemid 32405713)
31. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-572. (Pubitemid 12124384)
32. Singer JD, Willet JB: Applied Longitudinal Data Analysis. Modeling Change and Event Occurrence. New York, Oxford University Press, 2003.
33. Hofer SM, Sliwinski MJ: Design and analysis of longitudinal studies of aging; in Birren JE, Schaie KW (eds): Handbook of the Psychology of Aging, ed 6. San Diego, Academic Press, 2006, pp 15-37.
34. Thorvaldsson V, Hofer SM, Johansson B: Aging and late-life terminal decline in perceptual speed: a comparison of alternative modeling approaches. Eur Psychol 2006; 11: 196-203. (Pubitemid 44284743)
35. Hansen LA, de Teresa R, Davies P, Terry RD: Neocortical morphometry, lesion counts, and choline acetyltransferase levels in the age spectrum of Alzheimers disease. Neurology 1988; 38: 48-54. (Pubitemid 18028091)
36. Mann DMA: Pathological correlates of dementia in Alzheimers disease. Neurobiol Aging 1994; 15: 357-360. (Pubitemid 24194879)
37. Wilson RS, Li Y, Aggarwal NT, Barnes LL, McCann JJ, Gilley DW, Evans DA: Education and the course of cognitive decline in Alzheimer disease. Neurology 2004; 63: 1198-1202. (Pubitemid 39350017)
38. Sliwinski MJ, Hofer SM, Hall C, Buschke H, Lipton RB: Modeling memory decline in older adults: the importance of preclinical dementia, attrition, and chronological age. Psychol Aging 2003; 18: 658-671. (Pubitemid 37543429)
39. Thorvaldsson V, MacDonald SWS, Fratiglioni L, Winblad B, Kivipelto M, Laukka EJ, Skoog I, Sacuiu S, Guo X, Östling S, Börjesson- Hanson A, Gustafson D, Johansson B, Bäckman L: Onset and rate of cognitive change before dementia diagnosis: findings from two Swedish population-based longitudinal studies. J Int Neuropsychol Soc 2011; 17: 154-162.
40. Bäckman L, MacDonald SWS: Death and cognition: synthesis and outlook. Eur Psychol 2006; 11: 224-235. (Pubitemid 44284744)
41. Fratiglioni L, Winblad B, von Strauss E: Prevention of Alzheimers disease and dementia: major findings from the Kungsholmen Project. Physiol Behav 2007; 10: 98-104. (Pubitemid 47381378)